Definición y evolución del concepto de sarcopenia

IF 2 4区 医学 Q2 UROLOGY & NEPHROLOGY Nefrologia Pub Date : 2024-05-01 DOI:10.1016/j.nefro.2023.08.001
Maria Luz Sánchez Tocino , Secundino Cigarrán , Pablo Ureña , Maria Luisa González Casaus , Sebastian Mas-Fontao , Carolina Gracia Iguacel , Alberto Ortíz , Emilio Gonzalez Parra
{"title":"Definición y evolución del concepto de sarcopenia","authors":"Maria Luz Sánchez Tocino ,&nbsp;Secundino Cigarrán ,&nbsp;Pablo Ureña ,&nbsp;Maria Luisa González Casaus ,&nbsp;Sebastian Mas-Fontao ,&nbsp;Carolina Gracia Iguacel ,&nbsp;Alberto Ortíz ,&nbsp;Emilio Gonzalez Parra","doi":"10.1016/j.nefro.2023.08.001","DOIUrl":null,"url":null,"abstract":"<div><p>Sarcopenia and dynapenia are two terms associated with ageing that respectively define the loss of muscle mass and strength. In 2018, the European Working Group on Sarcopenia in Older People (EWGSOP) introduced the EWGSOP2 diagnostic algorithm for sarcopenia, which integrates both concepts. It consists of four sequential steps: screening for sarcopenia, examination of muscle strength, assessment of muscle mass and physical performance; depending on these last three aspects sarcopenia is categorised as probable, confirmed, and severe respectively. In the absence of validation of the EWGSOP2 algorithm in various clinical contexts, its use in haemodialysis poses several limitations: (a) low sensitivity of the screening, (b) the techniques that assess muscle mass are not very accessible, reliable, or safe in routine clinical care, (c) the sequential use of the magnitudes that assess dynapenia and muscle mass do not seem to adequately reflect the muscular pathology of the elderly person on dialysis. We reflect on the definition of sarcopenia and the use of more precise terms such as “myopenia” (replacing the classic concept of sarcopenia to designate loss of muscle mass), dynapenia and kratopenia. Prospective evaluation of EWGSOP2 and its comparison with alternatives (i.e. assessment of kratopenia and dynapenia only; steps 2 and 4) is proposed in terms of its applicability in clinical routine, resource consumption, identification of at-risk individuals and impact on events.</p></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"44 3","pages":"Pages 323-330"},"PeriodicalIF":2.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0211699523001261/pdfft?md5=bc976a82a2a633396ec04664b2f50fa0&pid=1-s2.0-S0211699523001261-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nefrologia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0211699523001261","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Sarcopenia and dynapenia are two terms associated with ageing that respectively define the loss of muscle mass and strength. In 2018, the European Working Group on Sarcopenia in Older People (EWGSOP) introduced the EWGSOP2 diagnostic algorithm for sarcopenia, which integrates both concepts. It consists of four sequential steps: screening for sarcopenia, examination of muscle strength, assessment of muscle mass and physical performance; depending on these last three aspects sarcopenia is categorised as probable, confirmed, and severe respectively. In the absence of validation of the EWGSOP2 algorithm in various clinical contexts, its use in haemodialysis poses several limitations: (a) low sensitivity of the screening, (b) the techniques that assess muscle mass are not very accessible, reliable, or safe in routine clinical care, (c) the sequential use of the magnitudes that assess dynapenia and muscle mass do not seem to adequately reflect the muscular pathology of the elderly person on dialysis. We reflect on the definition of sarcopenia and the use of more precise terms such as “myopenia” (replacing the classic concept of sarcopenia to designate loss of muscle mass), dynapenia and kratopenia. Prospective evaluation of EWGSOP2 and its comparison with alternatives (i.e. assessment of kratopenia and dynapenia only; steps 2 and 4) is proposed in terms of its applicability in clinical routine, resource consumption, identification of at-risk individuals and impact on events.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肌肉减少症概念的定义和演变
肌肉疏松症(Sarcopenia)和肌无力症(Dynapenia)是与衰老相关的两个术语,分别定义肌肉质量和力量的丧失。2018 年,欧洲老年人肌肉疏松症工作组(EWGSOP)推出了 EWGSOP2 肌肉疏松症诊断算法,将这两个概念融为一体。该算法由四个连续步骤组成:筛查肌肉疏松症、检查肌肉力量、评估肌肉质量和身体表现;根据后三个方面的情况,肌肉疏松症分别被分为可能、确诊和严重。由于 EWGSOP2 算法尚未在各种临床环境中得到验证,因此在血液透析中使用该算法存在一些局限性:(a)筛查灵敏度较低;(b)在常规临床护理中,评估肌肉质量的技术并不十分方便、可靠或安全;(c)按顺序使用评估肌力和肌肉质量的量级似乎并不能充分反映透析老人的肌肉病变。我们对 "肌肉疏松症 "的定义以及 "肌肉疏松症"(取代经典的 "肌肉疏松症 "概念,指肌肉量减少)、"动态肌肉疏松症 "和 "腓肠肌疏松症 "等更精确术语的使用进行了反思。我们建议对 EWGSOP2 进行前瞻性评估,并将其与替代方案(即仅评估 "桔皮样肌减少症 "和 "动态肌减少症";步骤 2 和 4)进行比较,以了解其在临床常规工作中的适用性、资源消耗、高危人群的识别以及对事件的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Nefrologia
Nefrologia 医学-泌尿学与肾脏学
CiteScore
3.40
自引率
7.70%
发文量
148
审稿时长
47 days
期刊介绍: Nefrología is the official publication of the Spanish Society of Nephrology. The Journal publishes articles on basic or clinical research relating to nephrology, arterial hypertension, dialysis and kidney transplants. It is governed by the peer review system and all original papers are subject to internal assessment and external reviews. The journal accepts submissions of articles in English and in Spanish languages.
期刊最新文献
Uso de los agonistas del receptor del péptido similar al glucagón tipo 1 en pacientes trasplantados renales La gota preclínica es frecuente en el paciente con enfermedad renal crónica estadio 3-5. Relevancia de la ecografía articular Renata, mi nefróloga, ¿puede la literatura infantil actuar como instrumento de sensibilización y prevención de la enfermedad renal? Proyección de la carga clínica y económica de la enfermedad renal crónica entre 2022 y 2027 en España: resultados del proyecto Inside CKD Aféresis terapéutica en gestante con hipercolesterolemia familiar heterocigota
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1